To include your compound in the COVID-19 Resource Center, submit it here.

Cyramza ramucirumab: Phase III data

The double-blind, international Phase III RAISE trial in >1,000 patients with mCRC showed that 8 mg/kg IV ramucirumab every 2 weeks plus FOLFIRI chemotherapy met the primary endpoint of improving OS

Read the full 312 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE